Today's Top Performers In Health Services

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 81 points (0.5%) at 17,082 as of Monday, Aug. 25, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,780 issues advancing vs. 1,159 declining with 188 unchanged.

The Health Services industry currently sits up 0.4% versus the S&P 500, which is up 0.4%. Top gainers within the industry include Smith & Nephew ( SNN), up 1.0%, Grifols ( GRFS), up 1.0%, Stryker Corporation ( SYK), up 0.9% and UnitedHealth Group ( UNH), up 0.7%. A company within the industry that fell today was Community Health Systems ( CYH), up 1.5%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. St Jude Medical ( STJ) is one of the companies pushing the Health Services industry higher today. As of noon trading, St Jude Medical is up $0.43 (0.7%) to $64.98 on light volume. Thus far, 313,675 shares of St Jude Medical exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $64.58-$65.24 after having opened the day at $64.79 as compared to the previous trading day's close of $64.55.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

St. Jude Medical, Inc. develops, manufactures and distributes medical devices for cardiac rhythm management, cardiovascular, and atrial fibrillation therapy areas worldwide. It operates in two divisions, Implantable Electronic Systems, and Cardiovascular and Ablation Technologies. St Jude Medical has a market cap of $18.4 billion and is part of the health care sector. Shares are up 4.2% year-to-date as of the close of trading on Friday. Currently there are 15 analysts who rate St Jude Medical a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates St Jude Medical as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full St Jude Medical Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Humana ( HUM) is up $1.08 (0.9%) to $124.27 on light volume. Thus far, 226,741 shares of Humana exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $123.30-$124.71 after having opened the day at $123.83 as compared to the previous trading day's close of $123.19.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Humana Inc., a health care company, offers a range of insurance products, and health and wellness services that incorporate an integrated approach to lifelong well-being. The company operates in Retail, Employer Group, Healthcare Services, and Other Businesses segments. Humana has a market cap of $19.0 billion and is part of the health care sector. Shares are up 19.4% year-to-date as of the close of trading on Friday. Currently there are 10 analysts who rate Humana a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates Humana as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Humana Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Abbott Laboratories ( ABT) is up $0.44 (1.0%) to $42.55 on light volume. Thus far, 1.0 million shares of Abbott Laboratories exchanged hands as compared to its average daily volume of 5.1 million shares. The stock has ranged in price between $42.27-$42.70 after having opened the day at $42.41 as compared to the previous trading day's close of $42.11.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Abbott Laboratories manufactures and sells health care products worldwide. Abbott Laboratories has a market cap of $63.6 billion and is part of the health care sector. Shares are up 9.9% year-to-date as of the close of trading on Friday. Currently there are 10 analysts who rate Abbott Laboratories a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Abbott Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Abbott Laboratories Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

AMD Rises Above the Competition; Loan Losses Mount for Big Banks -- ICYMI

AMD Rises Above the Competition; Loan Losses Mount for Big Banks -- ICYMI

McKesson Internal Review Clears Senior Management of Wrongdoing on Opioids

McKesson Internal Review Clears Senior Management of Wrongdoing on Opioids

Starbucks Surprises Wall Street With U.S. Sales Up a Paltry 2%

Starbucks Surprises Wall Street With U.S. Sales Up a Paltry 2%

Dow Jumps 238 Points as S&P 500, Nasdaq Also Climb

Dow Jumps 238 Points as S&P 500, Nasdaq Also Climb

Why Nashville, Denver, LA Should Reconsider Bids for Amazon HQ2

Why Nashville, Denver, LA Should Reconsider Bids for Amazon HQ2